MVM announces partial sale of its holding in Ambio

MVM Partners LLP has partially divested its stake in Ambio Holdings, Inc. (“Ambio”) a global leader in peptide manufacturing and development to The Carlyle Group (“Carlyle”) (NASDAQ: CG). Equity for the transaction comes from Carlyle Asia Partners V, its flagship $6.55 billion Asia fund that makes buyout and strategic investments across a wide range of sectors in Asia Pacific. MVM remains a significant shareholder of Ambio and maintains representation on the company’s Board of Directors.

Dr. Eric Bednarski, Partner of MVM, said, “MVM was the first institutional investor in Ambio. Since our investment in November 2014, Ambio has increased revenue more than 350% and built a highly profitable business. We are pleased to add Carlyle as an institutional partner and will continue working with management to drive future success of the company.”

Ambio is a primary supplier of complex peptide active pharmaceutical ingredients to the global pharmaceutical industry and its customers include many of the largest branded, generic and biotechnology companies. Ambio also has a rich and growing pipeline of proprietary drug development programs for generic versions of the world’s best-selling peptide drugs. The company is headquartered in North Augusta, South Carolina, and has manufacturing operations in Shanghai, China.

Ambio Holdings, Inc.

Ambio Holdings, Inc.
Peptide pharmaceuticals

Downloads

DownloadPress Release

Latest News

MVM announces partial sale of its holding in Ambio

MVM Partners announces the partial sale of its holding in Ambio to The Carlyle Group

Alliance Pharma acquires Nizoral rights in APAC region

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.

Alliance Pharma receives positive opinion for Diclectin

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.

Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.